Latest News Archive

Please select Category, Year, and then Month to display items

Thought-Leader Series: A culture of acceptance – is this South Africa’s greatest threat?

12 June 2023 | Story Samkelo Fetile

2023 UFS Thought-Leader Series

PRESENTS

a panel discussion titled

A culture of acceptance – is this South Africa’s greatest threat?

Watch the livestream (live on 13 July 2023)

The University of the Free State is pleased to announce the upcoming UFS Thought-Leader panel discussion titled “A Culture of Acceptance – South Africa’s Greatest Threat?” as part of the 2023 Thought-Leader Series. A public South African higher-education institution, The University of the Free State (UFS) recognises its responsibility to contribute to the public discourse. In collaboration with the Free State Literature Festival, this event will bring together esteemed thought leaders to shed light on the social, political, economic, and business landscape of South Africa and its implications for our future. The panel discussion will be facilitated by Prof Francis Petersen, Vice-Chancellor and Principal of the UFS.

Panel discussion presented on 13 July 2023

The general state of decay we are currently experiencing in our various structures of governance on nearly all levels is preventing the economic growth that our country so desperately needs to move forward. Our current national financial status is clearly the result of not only poor government performance, but also a totally deficient policy environment. Part of the threats currently facing our country is civil society’s attitude of accepting rampant corruption, crime, and economic degradation as if it is something inevitable and unavoidable. The question is: has our current situation created a society that has simply accepted its fate? Or has it created a society that has become more innovative and creative, actively navigating current challenges, and finding new solutions to societal issues independent of government? These are some of the aspects we look forward to discussing with the esteemed panel.

Date:	Thursday 13 July 2023
Time:	10:00-12:00
Venue:	Albert Wessels Auditorium, Bloemfontein Campus
RSVP:	https://events.ufs.ac.za/e/ThoughtLeaderPanel by 10 July 2023

Refreshments will be served.

For further information, contact Alicia Pienaar at pienaaran1@ufs.ac.za.

Some of the topics discussed by leading experts in 2022 included, among others, Crime in South Africa – who is to blame; Are our glasses half full or half empty; What needs to be done to power up South Africa?; and A look into the future of South Africa. This year’s webinar series commenced in April, when we discussed Threats to South Africa’s stability and security challenges.

Facilitator:	Prof Francis Petersen	Vice-Chancellor and Principal, UFS

Panellists:	Prof Bonang Mohale	President: Business Unity South Africa

	Prof Piet Croucamp	Senior Lecturer, Political Studies and International Relations: North-West University

	Dr Sipho Pityana	Founder and Chairman: Izingwe Capital (Pty) Limited

	Dr Lindie Koorts	Research Fellow: International Studies Group, UFS

Bios of speakers:

Prof Bonang Mohale

Bonang Mohale is the President of Business Unity South Africa (BUSA), Chancellor of the University of the Free State, Professor of Practice in the Johannesburg Business School (JBS) College of Business and Economics and Chairman of The Bidvest Group Limited, SBV Services and ArcelorMittal! He is a member of the Community of Chairpersons (CoC) of the World Economic Forum.

Mohale, a highly respected South African businessman, has held several leadership positions; namely, CEO of Business Leadership South Africa (BLSA), Vice President and Chairman of Shell South Africa (Pty) Ltd, Executive Vice President of SAA and MD of Otis (Pty) Ltd, among others. A vocal, agent courageous change, Mohale is known for his patriotism and active role in advancing the interests of South Africa. Mohale has a distinguished career and track record of leading and building successful companies and making significant advances in the transformation of these companies.

An avid writer, Mohale is the author of the bestselling books, “Lift As You Rise“ and “Behold The Turtle” which contain and reveals the issues he is passionate about. Mohale has been included in the Reputation Poll International’s (RPI) 2023 list of the ‘100 Most Reputable Africans’. The selection criteria are Integrity, Reputation, Transparency, Visibility, and Impact.

Prof Piet Croucamp

Professor Piet Croucamp teaches politics at the North-West University. His research interest is the social origins of violence. He has published extensively in both national and international scholarly journals.

Dr Sipho Pityana

Dr Sipho Mila Pityana is a business leader with extensive experience, having served in both executive and non-executive capacities on several local and international boards of blue-chip companies. He is the founder and Chairman of his private investment firm Izingwe. He is currently Chairman of the JSE-listed Redefine Properties, and non-executive Director of the Absa Bank Group. He is the former Chairman of AngloGold Ashanti Limited, and Munich Re of Africa. He also served as a lead independent Director of the Absa Group and an executive director of Nedcor Investment Bank, among others. He was the founding delegate of the National Economic Development and Labour Council (NEDLAC), and he was one of the founding members of the governing body of the Commission for Conciliation, Mediation and Arbitration. He served on the governing body of the International Labour Organisation (ILO). His passion for education has seen him serve as Registrar of the University of Fort Hare, Chairperson of the National Student Financial Aid Scheme (NSFAS), and former Chairperson of the Council of the University of Cape Town.

Dr Lindie Koorts

Dr. Lindie Koorts is a historian, biographer and author. She is a Research Associate at the University of the Free State's International Studies Group and a regular media commentator, who often writes on the links between current affairs and history.

Livestream

WATCH: 2023 UFS Thought-Leader Series (Live on 13 July 2023)

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept